Intervention Protocol

You have free access to this content

Opioids for treating dyspnoea in patients with chronic heart failure

  1. Fiona A Shearer1,
  2. Allan D Struthers1,
  3. Robin T Harbour2,*

Editorial Group: Cochrane Heart Group

Published Online: 17 FEB 2014

DOI: 10.1002/14651858.CD010991

How to Cite

Shearer FA, Struthers AD, Harbour RT. Opioids for treating dyspnoea in patients with chronic heart failure (Protocol). Cochrane Database of Systematic Reviews 2014, Issue 2. Art. No.: CD010991. DOI: 10.1002/14651858.CD010991.

Author Information

  1. 1

    University of Dundee, Division of Cardiovascular and Diabetes Medicine, Dundee, Scotland, UK

  2. 2

    Healthcare Improvement Scotland, Scottish Intercollegiate Guidelines Network (SIGN), Glasgow, UK

*Robin T Harbour, Scottish Intercollegiate Guidelines Network (SIGN), Healthcare Improvement Scotland, Delta House, 50 West Nile Street, Glasgow, G1 2NP, UK.

Publication History

  1. Publication Status: New
  2. Published Online: 17 FEB 2014




  1. Top of page
  2. Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

To assess whether opioid analgesics have a role in the control of dyspnoea in adults (aged 18 and over) with chronic heart failure. If the opioid reduces breathlessness in heart failure, this could potentially markedly improve the quality of life of people with this problem, as breathlessness is a major adverse symptom in heart failure. What is not entirely clear is whether opioids really do reduce breathlessness in heart failure and, if so, by how much and is it is enough to impact on quality of life?